Robbert Spaapen

Company: AstraZeneca

Job title: Associate Director

Seminars:

How Personalised Should Neoantigen-Targeted Cell Therapies & Cancer Vaccines Be? Unravelling the Limitations of Precision Neoantigen Therapies & Exploring Shared-Neoantigens for an Off-The-Shelf Approach 2:30 pm

Personalised therapies hold promise to provide the most optimal treatment plan available to patients, overcoming tumour heterogeneity and resistance. However, identifying specific neoantigens and developing precision therapies incurs a high cost, complex logistical planning, and a lengthy timeframe which is often too great for patients with late-stage disease. As such, the feasibility and scalability of…Read more

day: Pre-Conference Day